Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92,684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
Wang C, Yu X, Ke Y, Fu Y, Luo Y, Li Y, Bi Y, Chen X, Li L, Zhao X, Chen Z. Wang C, et al. Among authors: li y, li l. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0166823. doi: 10.1128/aac.01668-23. Epub 2024 Mar 14. Antimicrob Agents Chemother. 2024. PMID: 38483175 Free PMC article.
Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China.
Huang X, Xu L, Sun L, Gao G, Cai W, Liu Y, Ding H, Wei H, Ma P, Wang M, Liu S, Chen Y, Chen X, Zhao Q, Yu J, Song Y, Chen H, Wu H, Qin S, Li L. Huang X, et al. Among authors: li l. Front Pharmacol. 2019 Dec 11;10:1455. doi: 10.3389/fphar.2019.01455. eCollection 2019. Front Pharmacol. 2019. PMID: 31920648 Free PMC article.
Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China.
Guo PL, He HL, Chen XJ, Chen JF, Chen XT, Lan Y, Wang J, Du PS, Zhong HL, Li H, Liu C, Li LY, Hu FY, Tang XP, Cai WP, Li LH. Guo PL, et al. Front Pharmacol. 2021 Mar 25;11:569766. doi: 10.3389/fphar.2020.569766. eCollection 2020. Front Pharmacol. 2021. PMID: 33841131 Free PMC article.
Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings: A randomised, open-label and non-inferiority study from China.
Li L, He H, Lan Y, Chen J, Zhong H, Nie J, Chen X, Hu F, Tang X, Cai W. Li L, et al. Indian J Med Microbiol. 2018 Oct-Dec;36(4):513-516. doi: 10.4103/ijmm.IJMM_18_172. Indian J Med Microbiol. 2018. PMID: 30880698 Free article. Clinical Trial.
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.
Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, Chen YY, Liu L, Wang H, He Y, Zheng YH, Li LH, Chen JF, Yu JH, Zhu B, Zhao M, Sun YT, Lun WH, Xia W, Sun LJ, Dai LL, Jiang TY, Wang MX, Zheng QS, Peng HY, Wang Y, Lu RJ, Hu JH, Xing H, Shao YM, Xie D, Zhang T, Zhang FJ, Wu H; TALENT Study Team. Su B, et al. Among authors: li lh. Chin Med J (Engl). 2020 Nov 25;133(24):2919-2927. doi: 10.1097/CM9.0000000000001273. Chin Med J (Engl). 2020. PMID: 33252379 Free PMC article. Clinical Trial.
92,684 results
You have reached the last available page of results. Please see the User Guide for more information.